Modality
Degrader
MOA
PD-L1i
Target
CD3
Pathway
mTOR
CMLPancreatic Ca
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
~May 2018
→ ~Aug 2019
Phase 2
~Nov 2019
→ ~Feb 2021
Phase 3
~May 2021
→ ~Aug 2022
NDA/BLA
Nov 2022
→ Sep 2030
NDA/BLACurrent
NCT03002071
2,566 pts·Pancreatic Ca
2022-11→2030-09·Active
2,566 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-06-022mo awayEMA Filing· Pancreatic Ca
2030-09-284.5y awayPh3 Readout· Pancreatic Ca
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
NDA/BLA
Active
Catalysts
EMA Filing
2026-06-02 · 2mo away
Pancreatic Ca
Ph3 Readout
2030-09-28 · 4.5y away
Pancreatic Ca
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03002071 | NDA/BLA | Pancreatic Ca | Active | 2566 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 |